Literature DB >> 18367580

Comparison of serum humoral responses induced by oral immunization with the hepatitis B virus core antigen and the cholera toxin B subunit.

Katleen Broos1, Michiel E Janssens, Ine De Goeyse, Peter Vanlandschoot, Geert Leroux-Roels, Dirk Geysen, Yves Guisez.   

Abstract

The hepatitis B virus core (HBc) virus-like particle (VLP) is known as one of the most immunogenic antigens and carrier vehicles in different immunization strategies. Recent findings are suggesting the potential of the HBc VLPs as an oral immunogen. Here, we focus on the induction of serum humoral responses by oral administration of HBc VLPs in preparations substantially free of lipopolysaccharide and immunomodulating encapsidated RNA. The full-length HBc antigen was used, because the C-terminal arginine-rich tail may contribute to the immunogenicity of the antigen as the region is involved in cell surface heparan sulfate binding and internalization of the protein. Serum antibody levels and isotypes were determined following oral administration of the HBc VLPs with the perspective of using the HBc VLP as an immunostimulatory and carrier molecule for epitopes of blood-borne diseases in oral immunization vaccination strategies. Following oral administration of the HBc VLP preparations to mice, a strong serum humoral response was induced with mainly immunoglobulin G2a (IgG2a) antibodies, pointing toward a Th1 response which is essential in the control of intracellular pathogens. Intraperitoneal immunization with the HBc VLP induced a stronger, mixed Th1/Th2 response. Finally, a comparison was made with the induced serum humoral response following oral administration of the recombinant cholera toxin B pentamer, a commonly used oral immunogen. These immunizations, in contrast, induced predominantly antibodies of the IgG1 isotype, indicative of a Th2 response. These data suggest that the HBc VLP can be an interesting carrier molecule in oral vaccine development.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18367580      PMCID: PMC2394834          DOI: 10.1128/CVI.00382-07

Source DB:  PubMed          Journal:  Clin Vaccine Immunol        ISSN: 1556-679X


  71 in total

1.  Size-dependent immunogenicity: therapeutic and protective properties of nano-vaccines against tumors.

Authors:  Theodora Fifis; Anita Gamvrellis; Blessing Crimeen-Irwin; Geoffrey A Pietersz; Jie Li; Patricia L Mottram; Ian F C McKenzie; Magdalena Plebanski
Journal:  J Immunol       Date:  2004-09-01       Impact factor: 5.422

Review 2.  Vaccines that facilitate antigen entry into dendritic cells.

Authors:  Anita Gamvrellis; David Leong; Jennifer C Hanley; Sue D Xiang; Patricia Mottram; Magdalena Plebanski
Journal:  Immunol Cell Biol       Date:  2004-10       Impact factor: 5.126

3.  Cytokine induction by the hepatitis B virus capsid in macrophages is facilitated by membrane heparan sulfate and involves TLR2.

Authors:  Arik Cooper; Guy Tal; Ofer Lider; Yosef Shaul
Journal:  J Immunol       Date:  2005-09-01       Impact factor: 5.422

4.  Development of an enteric-coated, layered multi-particulate formulation for ileal delivery of viable recombinant Lactococcus lactis.

Authors:  Nathalie Huyghebaert; An Vermeire; Pieter Rottiers; Erik Remaut; Jean Paul Remon
Journal:  Eur J Pharm Biopharm       Date:  2005-06-20       Impact factor: 5.571

5.  Induction of neutralizing antibodies and Th1-polarized and CD4-independent CD8+ T-cell responses following delivery of human immunodeficiency virus type 1 Tat protein by recombinant adenylate cyclase of Bordetella pertussis.

Authors:  Laurent Mascarell; Catherine Fayolle; Cécile Bauche; Daniel Ladant; Claude Leclerc
Journal:  J Virol       Date:  2005-08       Impact factor: 5.103

Review 6.  Oral tolerance in the treatment of inflammatory autoimmune diseases.

Authors:  R M Wardrop; C C Whitacre
Journal:  Inflamm Res       Date:  1999-03       Impact factor: 4.575

7.  Oral vaccination of mice with human papillomavirus virus-like particles induces systemic virus-neutralizing antibodies.

Authors:  R C Rose; C Lane; S Wilson; J A Suzich; E Rybicki; A L Williamson
Journal:  Vaccine       Date:  1999-04-23       Impact factor: 3.641

8.  Native display of complete foreign protein domains on the surface of hepatitis B virus capsids.

Authors:  P A Kratz; B Böttcher; M Nassal
Journal:  Proc Natl Acad Sci U S A       Date:  1999-03-02       Impact factor: 11.205

9.  Measles virus hemagglutinin protein expressed in transgenic lettuce induces neutralising antibodies in mice following mucosal vaccination.

Authors:  D E Webster; S D Smith; R J Pickering; R A Strugnell; I B Dry; S L Wesselingh
Journal:  Vaccine       Date:  2006-02-20       Impact factor: 3.641

10.  Vaccine and adjuvant activity of recombinant subunit B of E. coli enterotoxin produced in yeast.

Authors:  E Fingerut; B Gutter; R Meir; D Eliahoo; J Pitcovski
Journal:  Vaccine       Date:  2005-09-07       Impact factor: 3.641

View more
  2 in total

1.  Immunogenic properties of a lettuce-derived C4(V3)6 multiepitopic HIV protein.

Authors:  Dania O Govea-Alonso; Néstor Rubio-Infante; Ana Lilia García-Hernández; Javier T Varona-Santos; Schuyler S Korban; Leticia Moreno-Fierros; Sergio Rosales-Mendoza
Journal:  Planta       Date:  2013-07-30       Impact factor: 4.116

Review 2.  Different applications of virus-like particles in biology and medicine: Vaccination and delivery systems.

Authors:  Zeinab Shirbaghaee; Azam Bolhassani
Journal:  Biopolymers       Date:  2016-03       Impact factor: 2.505

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.